Outlook Therapeutics initiates trial for ONS-5010 in Neovascular AMD
Outlook Therapeutics is conducting a multicenter, randomized trial to evaluate the safety and effectiveness of ONS-5010 in patients with neovascular AMD.
Company
Pharmaceutical intelligence for Outlook Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.